- The U.S. Food and Drug Administration on Thursday approved Amylyx Pharmaceuticals Inc’s drug for slowing progression of ALS, or amyotrophic lateral sclerosis, and potentially delaying death.
- Amylyx’s case for approval was built on a recent analysis of clinical trial data that it said showed the drug slows progression of the disease and extends life expectancy by nearly 10 months.
- Shares of the drugmaker were up nearly 7 percent in extended trading following the approval.
Trending
FDA Approves Amylyx Drug To Slow ALS Progression
